Treatment of patients under antiplatelet medication experiencing bleeding
An anti-platelet drug and platelet technology, applied in the direction of drug combination, medical raw materials derived from algae, blood diseases, etc., can solve problems such as bleeding complications that cannot be effectively solved
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0020] The following description focuses on embodiments of the invention that are applicable to therapeutic strategies for patients receiving antiplatelet drug therapy. Especially in the treatment of patients suffering from bleeding complications during / after surgery.
[0021] During physiological primary hemostasis, platelets immediately adhere to the exposed subendothelial membrane at the site of vascular injury, become activated, and release autocrine mediators such as thromboxane A2 (TXA2) and adenosine diphosphate (ADP), This changes the conformation of the fibrinogen receptor integrin αIIbβ3 into an activated state and eventually aggregates to form a fibrinogen-bridged plug. For TXA2, thromboxane / prostaglandin receptor-α (TPα) is the major isoform of platelets and, like the receptors for thrombin (PAR-1 and PAR-4), couples to Gα12 / 13 and Gαq . For ADP, Gαq-coupled P2Y1 receptors and Gαi2-coupled P2Y12 receptors have been identified on platelets. Signaling through the ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com